In a report released today, Peter Verdult from Citi maintained a Buy rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF335.00. The company’s shares closed last Friday at $261.49.
According to TipRanks, Verdult is ranked #2793 out of 8837 analysts.
Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $282.15.
The company has a one-year high of $323.78 and a one-year low of $233.12. Currently, Roche Holding AG has an average volume of 10.04K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG (RHHVF) Company Description:
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Read More on RHHVF:
- Roche upgraded to Hold from Sell at Deutsche Bank
- Viking seen âholding upâ against obesity competition as Roche presents data
- Viking upgraded to Strong Buy at Raymond James after ‘opaque’ competitor update
- Roche data falls short of Viking weight loss drug, says Truist
- Genentech announces results from CT-388 clinical trial
